ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VEC Vectura Group Plc

164.80
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Vectura Group Plc LSE:VEC London Ordinary Share GB00BKM2MW97 ORD 0.0271P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 164.80 164.80 165.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Vectura Share Discussion Threads

Showing 5476 to 5500 of 12050 messages
Chat Pages: Latest  230  229  228  227  226  225  224  223  222  221  220  219  Older
DateSubjectAuthorDiscuss
23/2/2017
22:49
Yes, whole presentation seems to be just a copy. Flutiform: China COPD programme due to read-out in H1 2017 and asthma studies.... STILL supposedly being initiated!
dontay
23/2/2017
20:58
Carpadium-at first glance, no change. The interim results presentation mentioned the completion of the China COPD trial in upcoming news flow but not mentioned in the presentations this year so doesn't seem very promising.
alexchry
23/2/2017
20:12
Today's global conference presentation held in US, haven't compared but likely little change to Feb's corporate briefing.
carpadium
23/2/2017
17:55
alexchry... I suppose it's utterly logical given all things being equal to presume the results will turn out the same, but you never know... I presume!As far as I'm aware the China trial was completed as expected at the end of last year and results are being collated with the expectation that the results would be published by the end of March... so could be anytime soon. Problem is... it's a horrible time to get anything out of China at this time of the year. New year celebrations in China are notorious and quite often mean staff going missing for at least six weeks, sometimes never to be seen again! Delays are the norm! That the trial will probably fail to meet its primary end point is probably already priced in anyway... but such is life that I doubt it would stop the share price making another dive when the reality of it kicks in!
dontay
23/2/2017
16:39
Dontay-which is why it was such a disappointment that the Europe Flutiform COPD trial was not a success. I do hope the China COPD trial is more successful but I'm not holding my breath, results are overdue.
alexchry
23/2/2017
15:06
Just a bit of statistical colour showing it's a pretty good market to be In!COPD is already the fourth leading cause of death worldwide, according to the World Health Organization (WHO); the WHO estimates that by the year 2020, COPD will be the third-leading cause of death and the fifth-leading cause of disability worldwide (Murray and Lopez 1997). COPD is the fastest-growing cause of death in developed nations and is responsible for over 2.7 million deaths per year worldwide. In the US, there are currently estimated to be 16 million people with COPD. There are estimated to be up to 20 million sufferers in Japan, which has the world's highest per capita cigarette consumption and a further 8–12 million in Europe. In 2000, COPD accounted for over 20 million outpatient visits, 3.4 million emergency room visits, 6 million hospitalizations, and 116,500 deaths in the US (National Center for Health Statistics 2002). Factors associated with COPD, including immobility, often lead to secondary health consequences (Polkey and Moxham 2006).
dontay
22/2/2017
14:37
No real reason for this rise, just reaching the top of its normal trading range. It's around this level that the traders usually step in and send it tumbling down to its lower end again and that also sets the conspiracy theorists up and running yet again! A good time to trade a few perhaps! Roll on the next announcement that might give some justification to a meaningful share price movement!
dontay
21/2/2017
17:36
fhmktg - if not it's very close,encouraging closing price touching 200 day MA on strong volume,need next two days to confirm.
AO

a0148009
21/2/2017
16:04
looks like its trying to end red. no way finnish over 146 shame, over all not a bad day at 16-03 pm off out now anything can happen in 27mins
pooroldboy55
21/2/2017
14:20
Is that a fully formed double bottom in place?Onwards and upwards!
fhmktg
21/2/2017
14:16
diesel-perhaps that's been it all along!
alexchry
21/2/2017
13:58
Trouble is when I get a warmer feeling it means something different these days!
diesel
21/2/2017
12:25
Hi alex
Also think things are about to change will be disappointed if we end the day in the red.

pooroldboy55
21/2/2017
11:48
pob-I've been waiting for you to say you were expecting the usual afternoon fall after the morning rise. A short while ago, I said I that had a warmer feeling about VEC, if the share price finishes above 146 today that feeling will get even warmer.
alexchry
21/2/2017
11:16
diesl why did you have to say that, now we are doomed.
pooroldboy55
21/2/2017
11:07
Feeling more relaxed with this for now, the brief visit to 130 didn't hold and I'm confident that the long term downtrend of the last year is now reversed. Wouldn't be surprised to see a stronger move northwards over the next couple of months. There I've done it now !
diesel
19/2/2017
19:47
What I find disappointing is that there does not seem to have been a clear explanation from VEC as to the exact reason for the disspute.
From a shareholders point of view i find poor ,and impossible to form an oppioion as to the likely outcome.

best1467
17/2/2017
11:10
PJ, Thats the conclusion I came to, but still unethical if GSK have tinkered with the formulation/process in full knowledge of VEC's IP in order to get around the additional patents.
rogerrail
17/2/2017
09:58
Popper Joe-I think you may be right. My worry is that GSK have far deeper pockets than VEC when it comes to funding litigation.
alexchry
17/2/2017
09:35
Roger, from the RNS in July announcing legal proceedings:

Patent licence and option-to-licence agreement
In August 2010, GSK and Vectura entered a license and option-to-licence agreement encompassing a number of Vectura patent families relating to various formulation technologies relevant to GSK's Ellipta® products. A number of these patents expire in 2016. GSK had the option to extend the term of the agreement by licensing additional patent families on or before 31 July 2016, but has formally notified Vectura that it does not wish to do so.

This is saying that it is patents that have expired. The RNS implies that VEC expected GSK to use the existing licence agreement to take options to use later patented technology, but that GSK had declined. So on the face of it, the situation would seem clear cut. If GSK are continuing to use VEC technology for which patents have expired, then VEC have no argument. If GSK are now using later VEC technology for which patents remain, then GSK have no argument.

However, I thought I read something last year at the time when this all cropped up, that suggested GSK had decided that they wanted to employ alternative technology to that for which VEC hold patents. So perhaps that is the crux of the matter. Is the technology that GSK is now using, or plans to use, close enough to that covered by VEC's patents or is it genuinely a different technology?

popper joe
16/2/2017
22:45
Perhaps the patent infringement concerns patents that had been filed but yet to be awarded at the time of the first license agreement hence the option to license?
rogerrail
16/2/2017
22:26
The lawsuit concerns the infringment of patents, what expired was the option to license the ip protected by those patents.
rogerrail
16/2/2017
21:19
Hi,

I do not hold at the moment. I got shaken out post SKP merger and have been sat on the sidelines since. There remains a little too much uncertainty for me to come back. VEC and SKP made sense for many years as a tie up IMO, but these things take a while to settle down.

regards,

Paul

polaris
16/2/2017
21:09
Paul, good to see you posting here. Have you retained a stake in VEC after the takeover? I would be very interested to read your views on VEC and it's prospects. Your posts on the SKP board were always much appreciated.
popper joe
16/2/2017
19:09
It was only a few years ago that the alleged slow sales of the GSK products in the pre-close statement for SKP caused the share to shed some 20+%. The announcement today just reinforces what i said at the time - this is BS! At the time i was more than convinced that the products would meet expectations in the listed timescale and likely before. I added that the agreement was poor by SKP to cap the possible royalties - i would have taken a fixed lower %age of sales and been non-capped. With the performance of the series i am sure the royalties could have more than doubled the 9M GBP cap.

regards,

Paul

polaris
Chat Pages: Latest  230  229  228  227  226  225  224  223  222  221  220  219  Older

Your Recent History

Delayed Upgrade Clock